Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 16/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 16/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 14/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.49 |
| ▸ | TSHR | P16473 | 13/20 | 0.49 |
| ▸ | USP2 | O75604 | 10/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.49 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.47 |
| ▸ | GLA | P06280 | 3/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21104428 | 0.86 | MAPT (0.44) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL13731823 | 0.86 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL13733067 | 0.85 | MAPT (0.45) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL13733770 | 0.82 | MAPT (0.45) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL13733774 | 0.82 | MAPT (0.45) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL27891369 | 0.80 | APLNR (0.47) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL1082046 | 0.77 | MAPK8 (0.50) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL23536009 | 0.77 | CYP1A2 (0.39) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL3832046 | 0.77 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL15472311 | 0.76 | MAPT (0.47) | CYP1A2CYP3A4CYP2C19LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | CYP1A2 2281/4885CYP3A4 3056/4885CYP2C19 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.